Skip to content
Open access

Dual-State Tumor-Activated RNA Delivery for Tumor-Selective and Precision Therapy.

Oct 2026 · ACS Applied Materials and Interfaces · Vol 18, pp. 59056-59073 · 0 citations · 54 references
Medicine

TL;DR

D-STAR establishes a dual-state adaptive RNA delivery framework that decouples systemic stability from activation potency, thereby offering a generalizable strategy for context-responsive precision RNA therapeutics.

Abstract

RNA therapeutics hold transformative potential for precision oncology; however, their systemic application remains constrained by a fundamental tradeoff between prolonged circulation stability and efficient intracellular activation. Conventional polyethylene glycol (PEG)-based carriers provide antifouling protection but lack tumor responsiveness, resulting in limited tumor accumulation and suboptimal gene expression. In this study, we developed a nanosystem, the dual-state tumor-activated RNA platform (D-STAR), which enables a dynamic transition from a stealth circulatory state to an activated transfection state through stepwise environmental alternation by recognizing a narrow pH window. At physiological pH, D-STAR maintains a negative surface potential to minimize nonspecific interactions and extend its blood circulation. Within the tumor microenvironment and endo-/lysosomal compartments, progressive protonation induces charge reversal and strengthens cationic activation, thereby enhancing tumor retention, cellular uptake, and cytoplasmic mRNA release. The systemic administration of D-STAR enabled tumor-selective mRNA expression with limited off-target organ distribution and markedly enhanced intratumoral reporter activity compared with PEG-based controls. The therapeutic delivery of human neutrophil elastase mRNA suppressed tumor growth and prolonged survival in a CT26 syngeneic model without systemic toxicity. Collectively, D-STAR establishes a dual-state adaptive RNA delivery framework that decouples systemic stability from activation potency, thereby offering a generalizable strategy for context-responsive precision RNA therapeutics.

Read PDF

Similar papers

Open access Oct 2026

Functional Nucleic Acid-Antibody Conjugates for Effective Tumor Targeted Therapy With Controllable Side Effects.

Antibody-guided therapeutics, including antibody-drug conjugates and radiopharmaceuticals, efficiently deliver payloads to tumor lesions, but the weeks-long half-life of antibodies promotes accumulation in normal tissues, increasing the risk of off-target toxicity. Although conventional linkers generally provide system...

Jia Liu, Zhi-Qiang Ren, Yuan Hu et al. · 0 citations
Review Oct 2026

Cascade liposomal delivery for glioblastoma through multi-stage biological checkpoints.

Although receptor-targeted liposomes provide promising opportunities for glioblastoma therapy, their clinical translation remains limited by sequential biological barriers encountered after systemic administration. Here, we establish a multi-stage checkpoint framework linking carrier properties with stage-specific tran...

Yan-Yu Zhang, Shao-Cong Weng, Qi-Hui Zhang et al. · 0 citations
Review Open access Oct 2026

Nanoparticle-Based Drug Delivery Systems for Anticancer Therapy: Microenvironment-Driven Strategies, Advances, and Challenges

Cancer remains a major global health challenge, and nanoparticle-based drug delivery systems have emerged as a promising strategy for targeted cancer therapy. However, clinical translation is still limited by an incomplete understanding of how nanoparticles navigate the tumor microenvironment (TME) throughout the deliv...

Meng-Xin Ban, Si-Fang Zhao, Zi-Yu Liu et al. · 0 citations
Oct 2026

Terminal-overhang-restricted CRISPR logic nanodevice for precision cancer therapy.

The limited precision of controlled drug release remains a major challenge for precision cancer therapy. Herein, a protein and nucleic acid dual-biomarker-responsive CRISPR AND logic nanodevice, termed LogiCas, is developed by integrating APE1 and miRNA-21 as dual inputs for precise tumor therapy. Leveraging the string...

Jing-Ge Zhang, Yu-He Yang, Yong-Hua Wu et al. · 0 citations
Review Open access Oct 2026

Stimuli-Responsive Nanocarriers in Oncology: Tumor Microenvironment Triggers, Overcoming Biological Barriers, and Clinical Reality

Conventional anticancer nano-therapies often rely on passive accumulation through the enhanced permeability and retention (EPR) effect, resulting in insufficient penetration of tumor tissue and heterogeneous cellular uptake. Smart nanocarriers that are able to respond to specific stimuli through conformational, charge-...

Di-Pu Pan, Shubhajit Sarkar, Souvik Adhikary et al. · 0 citations
Review Open access Oct 2026

Liposomes in Breast Cancer Therapy: Applications and Recent Research Progress

Breast cancer presents marked molecular and phenotypic heterogeneity, often requires prolonged treatment, and remains prone to drug resistance and recurrence. Conventional chemotherapy is still constrained by systemic toxicity and injury to non-target tissues. With a phospholipid bilayer surrounding an aqueous core, li...

Xin-Tong Wang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.